Document Detail


Codanin-1, the protein encoded by the gene mutated in congenital dyserythropoietic anemia type I (CDAN1), is cell cycle-regulated.
MedLine Citation:
PMID:  19336738     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Congenital dyserythropoietic anemia type I is an inherited autosomal recessive macrocytic anemia associated with ineffective erythropoiesis and the development of secondary hemochromatosis. Distinct erythroid precursors with internuclear chromatin bridges and spongy heterochromatin are pathognomonic for the disease. The mutated gene (CDAN1) encodes a ubiquitously expressed protein of unknown function, codanin-1. Based on the morphological features of congenital dyserythropoietic anemia type I erythroblasts and data on a role in cell cycle progression of codanin-1 homolog in Drosophila we investigated the cellular localization and possible involvement of codanin-1 during the cell cycle. DESIGN AND METHODS: Codanin-1 localization was studied by immunofluorescence and immune electron microscopy. Cell cycle expression of codanin-1 was evaluated using synchronized HeLa cells. E2F proteins are the main regulator of G(1)/S transition. An E2F1-inducible cell line (U20S-ER-E2F1) enabled us to study codanin-1 expression following ectopic E2F1 induction. Direct binding of E2F1 to codanin-1 promoter was assessed by chromatin immunoprecipitation. We used a luciferase-reporter plasmid to study activation of CDAN1 transcription by E2F1. RESULTS: We localized codanin-1 to heterochromatin in interphase cells. During the cell cycle, high levels of codanin-1 were observed in the S phase. At mitosis, codanin-1 underwent phosphorylation, which coincided with its exclusion from condensed chromosomes. The proximal CDAN1 gene promoter region, containing five putative E2F binding sites, was found to be a direct target of E2F1. CONCLUSIONS: Taken together, these data suggest that codanin-1 is a cell cycle-regulated protein active in the S phase. The exact role of codanin-1 during the S phase remains to be determined. Nevertheless this represents the first step towards understanding the function of the proteins involved in congenital dyserythropoietic anemia.
Authors:
Sharon Noy-Lotan; Orly Dgany; Roxane Lahmi; Nathaly Marcoux; Tanya Krasnov; Nissan Yissachar; Doron Ginsberg; Benny Motro; Peretz Resnitzky; Isaac Yaniv; Gary M Kupfer; Hannah Tamary
Related Documents :
7647308 - Cyclins, cdks and cancer.
11119718 - Analysis of fak-associated signaling pathways in the regulation of cell cycle progression.
21496868 - Hepatocyte nuclear factor-1β expression in clear cell adenocarcinomas of the bladder a...
2202778 - Changes in the incorporation of carbon derived from glucose into cellular pools during ...
18726128 - Monitoring growth phase-related changes in phosphatidylcholine-specific phospholipase c...
17625108 - Mesenchymal cells are required for functional development of thymic epithelial cells.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-03-31
Journal Detail:
Title:  Haematologica     Volume:  94     ISSN:  1592-8721     ISO Abbreviation:  Haematologica     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-05-01     Completed Date:  2009-09-25     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0417435     Medline TA:  Haematologica     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  629-37     Citation Subset:  IM    
Affiliation:
Pediatric Hematology Oncology, Schneider Children's Medical Center of Israel, 14 Kaplan Street, Petah Tiqva 49 202, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amino Acid Sequence
Anemia, Dyserythropoietic, Congenital / classification,  genetics*,  pathology
Base Sequence
Binding Sites / genetics
Blotting, Western
Cell Cycle / physiology*
Cell Division / physiology
Cell Line, Tumor
Chromatin Immunoprecipitation
E2F1 Transcription Factor / genetics,  metabolism
G2 Phase / physiology
Gene Expression / drug effects
Glycoproteins / genetics*,  metabolism
Hela Cells
Heterochromatin / metabolism,  ultrastructure
Humans
Leupeptins / pharmacology
Luciferases / genetics,  metabolism
Microscopy, Confocal
Microscopy, Immunoelectron
Molecular Sequence Data
Mutation*
Phosphorylation
Protein Binding
Tamoxifen / analogs & derivatives,  pharmacology
Chemical
Reg. No./Substance:
0/CDAN1 protein, human; 0/E2F1 Transcription Factor; 0/E2F1 protein, human; 0/Glycoproteins; 0/Heterochromatin; 0/Leupeptins; 10540-29-1/Tamoxifen; 133407-82-6/benzyloxycarbonylleucyl-leucyl-leucine aldehyde; 68392-35-8/4-hydroxytamoxifen; EC 1.13.12.-/Luciferases
Comments/Corrections
Comment In:
Haematologica. 2009 May;94(5):599-602   [PMID:  19407313 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dominant inheritance of a novel integrin beta3 mutation associated with a hereditary macrothrombocyt...
Next Document:  Preferential expansion of human umbilical cord blood-derived CD34-positive cells on major histocompa...